Friday, July 13, 201211:00 a.m. EDT
WALTHAM, Mass.--(BUSINESS WIRE)--
Repligen Corporation (NASDAQ:RGEN) today announced that Walter C.
Herlihy, Ph.D., President and Chief Executive Officer, will present a
corporate update at the JMP Securities Healthcare Conference 2012 in New
York. The Repligen presentation is scheduled for Friday, July 13, at
11:00 a.m. EDT.
A live webcast and subsequent archived replay of the presentation will
be available through the Investors section of Repligen’s corporate
website at www.repligen.com.
To access the live webcast, please log on through the Company’s website
approximately 15 minutes prior to the presentation.
About Repligen Corporation
Repligen Corporation is a leading
supplier of critical biologic products used to manufacture biologic
drugs. Repligen also applies its expertise in biologic product
development to RG1068, a synthetic hormone being developed as a novel
imaging agent for the diagnosis of a variety of pancreatic diseases. In
addition, the Company has two central nervous system (CNS) rare disease
programs in Phase 1 clinical trials. Repligen’s corporate headquarters
are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA
02453.
This press release may contain forward-looking statements within the
meaning of the federal securities laws. Investors are cautioned that
statements in this press release which are not strictly historical
statements including, without limitation, statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could”
and similar expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those anticipated, including, risks discussed from time to time in our
filings with the Securities and Exchange Commission. We expressly
disclaim any responsibility to update forward-looking statements, except
as required by law.
Repligen Corporation
Sondra S. Newman, 781-419-1881
Director
Investor Relations
snewman@repligen.com
Source: Repligen Corporation